TABLE 5.
Relationship between expression of MRPL15 and clinicopathological features of 81 patients with ovarian cancer
| Variables | Cases | MRPL15 staining | |||||
|---|---|---|---|---|---|---|---|
| (n = 81) | Low | High | |||||
| (‐) | (+) | (++) | (+++) | High positive rates (%) | p‐value | ||
| Age | 0.719 | ||||||
| <50 | 30 | 2 | 3 | 12 | 13 | 83.33 | |
| ≥50 | 51 | 1 | 6 | 18 | 26 | 86.27 | |
| FIGO stage | 0.035* | ||||||
| I‐II | 38 | 1 | 10 | 14 | 13 | 76.32 | |
| III‐IV | 43 | 2 | 1 | 15 | 25 | 93.02 | |
| Differentiation | 0.261 | ||||||
| Well‐moderate | 37 | 1 | 6 | 14 | 16 | 81.08 | |
| Poor | 44 | 2 | 3 | 17 | 22 | 88.64 | |
| Lymph node metastasis | 0.099 | ||||||
| No | 52 | 2 | 9 | 25 | 16 | 78.85 | |
| Yes | 20 | 1 | 0 | 3 | 16 | 95.00 | |
| No lymphadenectomy | 9 | 0 | 0 | 3 | 6 | 100.00 | |
| Pathologic type | 0.886 | ||||||
| Serous | 50 | 2 | 6 | 18 | 24 | 84.00 | |
| Mucinous | 6 | 0 | 1 | 1 | 4 | 83.33 | |
| Endometrioid | 7 | 0 | 1 | 5 | 1 | 85.71 | |
| Clear cell carcinoma | 6 | 0 | 0 | 1 | 5 | 100.00 | |
| Poorly differentiated adenocarcinoma | 12 | 1 | 1 | 6 | 4 | 83.33 |
Abbreviation: FIGO, International Federation of Gynecology and Obstetrics.
*
p < 0.05.